Amarin Corp Plc (AMRN)

[Number sleven]

Tatsumaki, Being cheaper will help. What I am talking about is the automatic pharmacy substitution. Approval of a self emulsifying version of Vascepa will require a NDA. That makes it a new drug. The current generic versions should not be considered AB rated generic substitutes for that drug.
Amarin will lose Exclusivity for the R-IT indication in December. The generic companies may not file ANDA's since they already have access to the market. If they do they need to prove that the R-IT patents are invalid.
Sleven,